Suzuki, S.; Toyoma, S.; Kawasaki, Y.; Koizumi, K.; Iikawa, N.; Shiina, K.; Endo, T.; Abe, T.; Kouga, T.; Yamada, T.
Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Medicina 2021, 57, 1151.
https://doi.org/10.3390/medicina57111151
AMA Style
Suzuki S, Toyoma S, Kawasaki Y, Koizumi K, Iikawa N, Shiina K, Endo T, Abe T, Kouga T, Yamada T.
Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Medicina. 2021; 57(11):1151.
https://doi.org/10.3390/medicina57111151
Chicago/Turabian Style
Suzuki, Shinsuke, Satoshi Toyoma, Yohei Kawasaki, Koh Koizumi, Nobuko Iikawa, Kazuhiro Shiina, Tentaro Endo, Tomoe Abe, Teppei Kouga, and Takechiyo Yamada.
2021. "Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma" Medicina 57, no. 11: 1151.
https://doi.org/10.3390/medicina57111151
APA Style
Suzuki, S., Toyoma, S., Kawasaki, Y., Koizumi, K., Iikawa, N., Shiina, K., Endo, T., Abe, T., Kouga, T., & Yamada, T.
(2021). Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Medicina, 57(11), 1151.
https://doi.org/10.3390/medicina57111151
